scholarly article | Q13442814 |
P50 | author | Pietro Ravani | Q87969721 |
Gian Marco Ghiggeri | Q37841673 | ||
Gianluca Caridi | Q42709622 | ||
Alice Bonanni | Q55602759 | ||
P2093 | author name string | Roberta Rossi | |
P2860 | cites work | Beyond ecto-nucleotidase: CD39 defines human Th17 cells with CD161 | Q26830436 |
Structure of the Fab fragment of therapeutic antibody Ofatumumab provides insights into the recognition mechanism with CD20 | Q27655426 | ||
Rituximab targets podocytes in recurrent focal segmental glomerulosclerosis | Q30541740 | ||
Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy | Q33360327 | ||
Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature. | Q33385806 | ||
Two structurally different rituximab-specific CD20 mimotope peptides reveal that rituximab recognizes two different CD20-associated epitopes | Q33395923 | ||
Non-infectious pulmonary toxicity of rituximab: a systematic review | Q34096300 | ||
Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis | Q34327451 | ||
The anti-CD20 antibody rituximab reduces the Th17 cell response | Q58998900 | ||
Rituximab treatment for severe steroid- or cyclosporine-dependent nephrotic syndrome: a multicentric series of 22 cases | Q61849364 | ||
The nephrotic syndrome in adults with 'minimal change' glomerular lesions | Q68810071 | ||
Getting a foothold in nephrotic syndrome | Q73606344 | ||
Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome | Q81140679 | ||
Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment | Q83283173 | ||
Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood--follow-up after CD19 recovery | Q84654866 | ||
Short-term efficacy of rituximab versus tacrolimus in steroid-dependent nephrotic syndrome | Q84951697 | ||
Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome | Q87423069 | ||
Ofatumumab for rituximab-resistant nephrotic syndrome | Q87522692 | ||
Efficacy and Safety of Treatment with Rituximab for Difficult Steroid-Resistant and -Dependent Nephrotic Syndrome | Q34362680 | ||
IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma | Q34440364 | ||
CD20-mediated apoptosis: signalling through lipid rafts | Q34969960 | ||
Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial | Q35030581 | ||
Rituximab resistance | Q35041270 | ||
Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial | Q35540009 | ||
Rituximab in children with resistant idiopathic nephrotic syndrome | Q35982341 | ||
Rituximab in Children with Steroid-Dependent Nephrotic Syndrome: A Multicenter, Open-Label, Noninferiority, Randomized Controlled Trial | Q36003160 | ||
Long-term prognosis of adult patients with steroid-dependent minimal change nephrotic syndrome following rituximab treatment | Q36151665 | ||
Ceramide-enriched membrane domains | Q36286893 | ||
Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome | Q36509322 | ||
Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome | Q37275486 | ||
Rituximab treatment of adult patients with steroid-resistant focal segmental glomerulosclerosis | Q37297636 | ||
Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis: report of four cases and review of the literature. | Q37326185 | ||
Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project | Q37568787 | ||
Rituximab in steroid-dependent or frequently relapsing idiopathic nephrotic syndrome | Q37670299 | ||
Familial FSGS. | Q38244354 | ||
Regulatory T cells and minimal change nephropathy: in the midst of a complex network | Q38543132 | ||
Pathogenesis of lipoid nephrosis: a disorder of T-cell function | Q41509804 | ||
Rituximab versus azathioprine for maintenance in ANCA-associated vasculitis | Q41676109 | ||
Low-dose ofatumumab for rituximab-resistant nephrotic syndrome. | Q41728530 | ||
Cyclosporine in patients with steroid-resistant nephrotic syndrome: an open-label, nonrandomized, retrospective study | Q42639974 | ||
Single infusion of rituximab for persistent steroid-dependent minimal-change nephrotic syndrome after long-term cyclosporine | Q43202423 | ||
An open study of B lymphocyte depletion in systemic lupus erythematosus | Q44183280 | ||
Long-term follow-up after rituximab for steroid-dependent idiopathic nephrotic syndrome | Q46912071 | ||
Rituximab treatment of idiopathic membranous nephropathy | Q46945049 | ||
Single dose of rituximab for refractory steroid-dependent nephrotic syndrome in children | Q47864240 | ||
Fatal pulmonary fibrosis after rituximab administration | Q47935891 | ||
Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial. | Q50664664 | ||
Rituximab in refractory nephrotic syndrome. | Q53063316 | ||
Pathology of the nephrotic syndrome in children: a report for the International Study of Kidney Disease in Children. | Q53452950 | ||
P433 | issue | 4 | |
P921 | main subject | nephrotic syndrome | Q504790 |
idiopathic nephrotic syndrome | Q55787775 | ||
P304 | page(s) | 710-720 | |
P577 | publication date | 2015-11-19 | |
P1433 | published in | Clinical Journal of the American Society of Nephrology | Q15757929 |
P1476 | title | Anti-CD20 Antibodies for Idiopathic Nephrotic Syndrome in Children | |
P478 | volume | 11 |